NN 9926

Drug Profile

NN 9926

Alternative Names: GLP-1 SG GIPET; Long-acting GLP-1 analogue; NN-9926; NNC 0113-0987; Non-invasive GLP-1 - Novo Nordisk; OG-987-GT; Oral GLP-1 987 C10; SG GIPET

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Novo Nordisk
  • Class Antihyperglycaemics
  • Mechanism of Action Glucagon like peptide 1 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Type 2 diabetes mellitus

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Type-2-diabetes-mellitus(In volunteers) in Germany (PO, Tablet)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Type-2-diabetes-mellitus(In volunteers) in United Kingdom (IV)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Type-2-diabetes-mellitus(In volunteers) in United Kingdom (PO, Tablet)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top